An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis

Last updated: February 26, 2025
Sponsor: Taisho Pharmaceutical Co., Ltd.
Overall Status: Completed

Phase

3

Condition

Joint Injuries

Musculoskeletal Diseases

Bone Diseases

Treatment

TS-152

Clinical Study ID

NCT04077567
TS152-3002-JA
  • Ages > 20
  • All Genders

Study Summary

To evaluate the long-term safety and efficacy of TS-152 in subjects with Rheumatoid Arthritis who have completed the previous study (TS152-3000-JA study or TS152-3001-JA study).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. At visit1(-4 weeks), Subject must be fully informed about the study and must obtainwritten informed consent from the subject himself.

  2. At Visit2(0 week), Subjects must have completed the previous study (TS152-3000-JA orTS152-3001-JA) ,and must have completed all evaluations required at the follow-upvisit.

etc.

Exclusion

Exclusion Criteria:

  1. Subjects who had serious adverse drug reactions in the previous study.

  2. At Visit1(-4 weeks) or Visit2 (0 week), Subjects who have not recovered fromclinically important adverse events.

etc.

Study Design

Total Participants: 401
Treatment Group(s): 1
Primary Treatment: TS-152
Phase: 3
Study Start date:
October 01, 2019
Estimated Completion Date:
April 28, 2023

Connect with a study center

  • Taisho Pharmaceutical Co., Ltd selected site

    Tokyo,
    Japan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.